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ABSTRACT 
BACKGROUND: 
Poly cystic ovarian syndrome is a heterogenous collection of signs and symptoms together 
form a spectrum of disorder where the clinical manifestation varies from mild to severe 
disturbances of reproductive endocrine and metabolic function. The pathophysiology of 
PCOS appear to be multifactoial and polygenic. AMH is a homodimeric glycoprotein which 
belongs to transforming growth factor β family. It is expressed in granulosa cells of 
secondary , preantral and small follicles ≤ 4 mm in diameter. 
OBJECTIVE: 
 To estimate the levels of AMH  in PCOS patients and Normoovulatory women and to 
correlate the same in both the groups. 
MATERIALS & METHODS 
This study was conducted  in Chennai Medical College Hospital And Research Centre, 
Irungalur, Trichy.Thirty normal menstruating women and thirty women with anovulatory 
pcos with spontaneous or induced progesterone cycle were included in the study.  Serum 
samples were collected and analysed for AMH and  ultrasonographic measurement of AFC 
and ovarian volume were done in all subjects. 
RESULTS: 
 The mean value of AMH among cases (11.28 ± 5.29) and controls (3.5 ± 1.46) were 
statistically significant by student’s t test (p= < 0.001). AMH  values in both groups were 
negatively  correlated with age and positively correlated with antral follicular count. 
Furthermore the ovarian volume in cases were positively correlated with AMH and was 
statistically significant. 
CONCLUSION: 
 The present study demonstrated that in PCOS serum AMH levels increased 2 to 3 fold higher 
than in control women. The raised AMH  gives us the clue for the mechanism behind the 
anovulation in PCOS. AMH levels have a major inhibitory role during folliculogenesis thus 
leading to anovulation in PCOS. 
 ABREVATION 
                  
                   AFC                                    Antral follicle count 
AMH                                   Antimullerian hormone 
AMHR                                Antimullerian hormone receptor 
ART                                    Assisted reproductive technology 
COH                                   Controlled ovarian hyperstimulation 
E2                                        Estradiol hormone 
ELISA                                 Enzyme linked immunosorbent assay 
FSH                                     Follicle-stimulating hormone 
GIFT                                   Gamete intrafallopian tube transfer 
GnRH                                  Gonadotropin-releasing hormone 
IVF                                      In vitro fertilization 
LH                                       Luteinizing hormone 
MIS                                     Mullerian-inhibiting substance 
PRL                                     Prolactin hormone 
T3                                        Triiodothyronine 
T4                                        Thyroxine 
TSH                                     Thyroid-stimulating hormone 
TVUS                                  Trans vaginal ultrasound 
OV                                      Ovarian volume 
 
Introduction                  
The human ovary function as to  nurture, development and  release of mature 
oocyte which is need for the  secretion of steroidal hormones and fertilisation which 
stimulate the  development and growth of secondary sexual characters. A female fetus 
contain 7 million oocytes at  birth ,(1- 2) million at puberty and 40,0000 oocyte
1
 at the 
onset of the menstrual cycle
1
.A fixed proportion of the remaining oocytes becomes 
recruited by the gonadotrophins from which one or two will achieve dominance and 
will progress to ovulation. 
The quality and quantity of oocytes is determined by the term ovarian 
reserve
2
.The reproductive potential is important and is measured by ovarian reserve 
4
.Ovarian reserve decline with age and the variations is  significant in individual with 
the onset of  decline in age and the assessment of the ovarian reserve is needed
3
. 
Measurement of ovarian reserve in disease like Polycystic Ovarian Disease aid 
in mode of selection of mode of treatment. The clinical features of PCOS is a 
spectrum of disorder with a heterogeneous collection of signs and symptoms from 
mild to serve disturbance of metabolic functions and Reproductive Endocrine. The 
Polycystic Ovarian Syndrome pathophysiology appears to be polygenic and 
multifactorial. The most common endocrine disorder is PCOS of the Reproductive age 
group women. Polycystic Ovarian Syndrome is diagnosed based on the presence of 
any two of the following three criteria according to Rotterdams (2003)
5
,They are 
i) Oligo and Anovulation –menstrual cycle longer than 35 days or less than 
eight menstruations periods per year. 
ii)       Hyperandrogenism –(clinical/biochemical) -as per the Ferrimann-Gallway 
scoring system designed to assess the clinical manifestation of Hirsutism
6
.As per 
the scoring system the Masculine part of body hair growth is described in four 
degrees on different body places Viz. Upper lip ,Chin ,Chest ,Lower leg ,Upper 
back ,Upper abdomen ,Lower back, Arm, , ,Lower abdomen ,Forearm and 
Thighs.Biochemical manifestations is Hyperandrogenism which is calculated by 
Free androgen Index (FAI) from testosterone and sex hormone binding 
globulin(SHBG) 
7,8
. 
ii) Polycystic Ovaries- Where at least one of the ovaries should have follicles 
measuring 2-9 mm in diameter  or should be of 12 follicles (or) an  
increase in  Ovarian volume (>10cm
3
).
9
  
A wide variety of heterogenisity of signs and symptoms exist in PCOS women 
and in some PCOS subjects who can exist without any clinical signs and symptoms 
which can be expressed over time. 
PCOS is prevalent in young Reproductive age group where the distribution 20-
30%
10,11
. Presence of Insulin Resistance, Dyslipidemia and Central obesity which 
might lead to the complications of Diabetes and Cardiovascular disease in PCOS 
women. Women with PCOS have been under the  increased risk for Endometrial, 
Breast, and Ovarian cancer. 
The functional potential of the Ovary reflects the number and activity of the 
oocytes present within the Ovary which refers to ovarian reserve. The ovarian reserve 
constitutes the oocytes and the ovarian follicular pool size that it diminishes with 
increasing age. Ovarian reserve can be assessed by various markers Viz .serum FSH, 
serum Estradiol , Ovarian volume , antral follicle count etc., 
Ovarian reserve are assessed by Biochemical parameter and ultrasound 
parameter. Biochemical parameters are measurement of Hormones such as FSH and 
E2 .Measurement Of FSH and E2 on Day3
12
 has limitations in PCOS patients as it is 
very difficult to predict the appropriate time owing to irregular cycles. Antral 
follicular count by ultra sonogram is a better marker for assessing the Ovarian reserve 
.The characteristic of the Polycystic Ovary are variable and may be  subtle and need 
lot of expertise  to precisely determine the AFC count. Owing to the above said 
limitations there is a need of a marker which correlates well with ovarian reserve.So 
as to ascertain the functional ability of Ovary and intervention of ovarian pathology 
for conception.AMH level decreases steadily with increasing age from 24 to 50 years 
of  age
13
.Reports documented AMH as a predictor of age related reductions in 
fecundability in the general populations. 
AMH concentration in the serum is directly related to the antral follicle count 
and is a better indicator of Ovarian reserve when compared to FSH and Estradiol 
level
14
.As the concentrations of AMH is unaffected by gonadotrophins it is feasible to 
measure AMH throughout the cycle
15
.With this background, the present study aims at 
measuring AMH levels in normoovulatory and Polycystic Ovarian Syndrome to 
assess the Ovarian reserve.  
There are few studies done in correlation of AMH with ultrasound findings 
,hormonal profiles in normoovulatory/PCOS.The present study elucidates the 
correlation of AMH in normoovulatory and PCOS subjects related to Biochemical 
(hormonal)and ultrasonographic findings .This will aid us to include measurement of 
AMH in PCOS subjects in diagnosing and for  better management . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Aim of the study                
To Study the relationship of Antimullerian hormone among Normoovulatory 
and   Poly Cystic Ovarian Syndrome women. 
Objectives of the study: 
1. To study the level of AMH in PCOS   patients 
2. To study of the level of AMH in normoovulatory women. 
3. To determine correlation of AMH levels in normoovulatory women and PCOS 
women . 
                                                                                          
                                                  
                                                
 
 
 
 
 
 
 
Ovary 
Ovary undergoes through a number of stages as it passes from the stage of 
development. The development is initiated at 30 days after the post conception by 
formation of a genital ridge, followed at about 35 days by an indifferent gonad, at 
42 days developed into an embryonic ovary (6 weeks), and at about 8weeks an 
early fetal ovary is developed , at 16 weeks a late fetal ovary, and perinatal ovary 
develops by the end of  28 weeks. Functional ovary develops from the germ cells. 
The sex gonadal of an embryo becomes evident at about 6 weeks post conception, 
Fetal early weeks span for about 8- 16 weeks. Primordial follicles are 
formed by the 12
th
 week ,when the epithelial cells surround ova and after 16 weeks 
of gestation they form the late fetal stage. The cuboidal epithelial cells emerge 
from the growing follicle by 28
th
 weeks of gestation .The stroma later differentiate 
into theca interna which demonstrates features of steroidogenesis, the presence of 
3β-hydroxysteroid dehydrogenase 16 
 Paired gonadal structures the ovaries which lie suspended between the pelvic 
wall and the uterus by the infundibulopelvic and uteroovarian ligaments. Adult 
ovaries are ovoid in shape and they measuring 5 X 3 X 3 cm.There is variation in 
dimension of the ovary in respect to hormonal changes during the menstrual cycle 
and also along with age. Normally small corpus luteum along with small cystic 
follicles are  seen under the surface of the ovary. Each ovary consists of outer 
cortex composed of specialized stroma and follicles of various sizes, the inner 
medulla occupies a small portion of ovary made of fibromuscular tissue and blood 
vessels.  
Ovarian function 
The ovaries have two functions: the production of ova and the production 
of hormones .Both these functions are controlled through the hypothalamic- 
pituitary ovarian axis by endocrine, paracrine and autocrine pathways. 
Production of ova 
The ovary of the female child at birth contains all the primary oocytes 
which are scattered amongst the mesenchymal stromal cells of the medulla and 
cortex. A female fetus contains 7 million oocytes at birth. It is further reduced 
during childhood so that at puberty the figure is about 400000 oocytes at the onset 
of menstrual cycle .Of these not more than 500 are designated to mature during the 
individual’s lifetime and the remainder will be lost by degenerative process.  
During childhood, the ovary grows in size by an increase in stroma .Nevertheless, 
ova do attempt to ripen from time to time but they fail to complete the process and 
become blighted
 16
 
Menstrual Cycle Physiology 
 This includes the proliferation of the uterine cells and the follicular maturity attained 
parallels with the production of the hormones. The cycle starts from the development 
of the follicles to the implantation of the embryo in the uterus or if no fertilization 
occurs it may lead to mensturation. Various  
The  Menstrual  Cycle. 
 
 
Pic: 1:- shows the top panel shows the cyclic changes of FSH, LH, estradiol (E2), 
and progesterone (P) relative to the time of ovulation. The bottom panel 
correlates the ovarian cycle in the follicular and luteal phases and the 
endometrial cycle in the proliferative and secretory phases. 
(Jonathan S.Berek.Editor.Novak’s Gynecology.Lippincott Williams 
&Wilkins;2002.13
th
 editionpathological and physiological changes may lead to 
disorders in the menstrual cycle, including recurrent miscarriage, infertility and 
malignancy.   
Normal Menstrual Cycle 
           The ovarian and the uterine cycles are the two phase of   menstrual cycle. The uterine 
cycle is divided into the proliferative and secretory phases while the ovarian cycle is divided 
into follicular and luteal phases. The  Follicular phase is the growth and recruitment of a 
dominant follicle which proceeds to the process of ovulation .The entire process is   under 
the control of hormones. The Normal duration of the menstrual cycle is from 21 to 35 days 
cycle .This includes the follicular phase with a duration of 10 to 14 days which is in turn has 
variation depending on the individuals. Luteal phase duration is of 14 days which starts 
from the day of ovulation to the onset of menses. The menstrual flow is of about two to six 
days and with an average menstrual blood loss about approximately 20 to 60 ml per cycle. 
Variations from these would lead to an irregular cycles 
17
 
Follicular development:-   Primodial follicle  
Follicular epithelial cells are of single layer and they surround the oocytes 
measuring about 25-30 μm in diameter. In young individuals there is more of 
primordial or primary follicles of about 38,000. As these individuals reach the age 
of 40 their follicular number is reduced to about 8000. At the time of menopause 
there are only a few follicles or even reduced extremely to one or two in later 
period of life. A follicle grows upto the antral stage all along the period of fetal life 
and also during the period of infancy 
18
 
Growing follicle: At 28 wks of gestation the follicular growth begins and continues upto 
menopause. Only of about 10% of these follicles are in the active growing period the rest  
The  pulsatile  secretion of GnRH 
 
 
 
 
 
PIC 2: shows the  pulsatile  secretion  of  GnRH  in  the  follicular  and  luteal  phases  of  
the cycle. 
 
(Jonathan S.Berek.Editor.Novak’s Gynecology.Lippincott Williams &Wilkins;2002.13th edition) 
being inactive. These inactive follicles are called as Primordial follicles or Primary follicles 
.The active growing follicles is called secondary follicles and the tertiary the preovulatory 
follicles
16
.The secondary follicles are further divided into pre- antral , antral and 
preovulatory  follicles .In the preantral-the follicles grow  upto size of 0.4mm and antral 
follicles grow upto 1-2mm. It require about 50 days to grow to a preovulatory stage . Only 
one or two follicles attain the preovulatory stage during each menstrual cycle
18.
 The pool of 
primordial follicle is formed in the neonatal period and is considered infinite.  
The oocytes continue to grow to antral stage. The selected follicles compete with each 
other for growth inducing FSH .In response to rise of FSH the preantral follicles begin to 
secrete estrogens. This have a negative feedback on FSH. Follicles with fewer FSH receptor 
will not be able to develop further, they will show retardation of their growth and become 
atretic . Eventually only one follicle will be recruited and  is called the dominant follicle. 
This dominant follicle which will grow up to 20mm in diameter to become the preovulatory 
follicle which stimulate the estrogen hormone to a high level of for a period of  48 hrs
18.
 
Ovulation 
By the end of follicular phase or phase of the 13
th
 day of menstrual 
cycle.The preovulatory follicle release a single oocyte and it is called ovulation. 
This needs the midcycle LH surge and it is responsible for the ovulation 
20 
 
Atretic follicles 
The primodial follicles which are of about one to two million at the time of 
birth and only four hundread ovulate among them . The rest of the follicles 
undergoes a process called atresia and disappears. This follicular atesia is more 
pronounced in pregnancy, premenarche, and PCOS women.The androstenedione is  
 Neurologic  connections  to  the  pituitary. 
 
 
 
PIC 3:- shows the  hypothalamus  and  its  neurologic  connections  to  the  pituitary. 
(Jonathan S.Berek.Editor.Novak’s Gynecology.Lippincott Williams &Wilkins;2002.13th 
edition) 
 
produced by the theca interna cells in the absence of granulosa which cannot be 
converted to estradiol and they are responsible for the androgenic activity in PCOS 
18
. 
Corpus luteaum 
Post ovulation the oocytes are discharged from the follicles and the 
ruptured follicles tends tocollapse .This leads to a scared theca interna called 
corpus luteum which exists for 14 days after ovulation and begin to degenerate if 
fertilization does not occur. Then menstrual flow is regulated by estrogens 
18
 .In 
the absence of fertilization, post ovulation on the 14 days the corpus luteum 
disappear.
20 
Ovarian hormones:-    Estradiol 
Estradiol (E2) is a C18 steroid with the presence of phenolic hydroxyl 
group at C-3 on an aromatic ring, and either a hydroxyl group (estradiol) or a 
ketone group (estrone) at C-17, which synthesized from its precursor   
cholesterol.The site of secretion is primarily from  the ovary, the placenta, and also 
in  also from adrenal cortex. The secretion is very low after menopause. About 
89% of the estrogen is  bound to sex hormone binding globulin in blood stream. It 
is bound to albumin also to a lesser extent. Estrogen activity is affected by the  
estradiol-receptor complexes which is situated in the target site like the uterus, 
breast, hypothalamus and pituitary gland. 
20
 
Pituitary gonadotropins:-     Follicle stimulating hormone 
Follicle stimulating hormone has two subunits α and β and is a glycoprotein 
with a molecular mass of 35.5 KDa. The β- subunit is unique while the α-subunit  
The hypothalamic  secretory  function 
 
 
PIC4 :-showsthe hypothalamic  secretory  products  function  as pituitary- releasing  
Factors  that  control  the  endocrine function of the ovaries, the thyroid, and the 
adrenal gland 
 (Jonathan S.Berek.Editor.Novak’s Gynecology.Lippincott Williams &Wilkins;2002.13th 
edition) 
 is similar to other pituitary hormones (20). Follicle Stimulating Hormone (FSH) is 
under the control of the gonadotropin-releasing hormone (GnRH) which causes its 
release from the anterior pituitary gland and the hormone is transported via the 
blood stream to the ovary its target  site .FSH stimulates the growth of ovarian 
follicles in the ovary . FSH also stimulates secretion of estrogen by the follicle 
cells .
19
 
Luteinizing hormon 
Luteinizing hormone (LH) is a glycoprotein with a molecular weight of 30 
Kilo Daltons 
18
.The gonadotropin-releasing hormone (GnRH) releases the 
Lutenizing Hormone from the anterior pituitary and the hormone is taken to the 
targeted site via the blood. LH then stimulates that follicle until the stage of corpus 
luteum 
19
.,Lutenizing Hormone is under the control of the  Gonadotrophin 
Releasing hormone which in turn stimulates the secretion of sex steroids 
Hormones from the gonads. This operates by a negative feedback loop 
mechanismon the, sex steroids which inturn inhibits the  secretion of GnRH which 
inturn has a  negative effects on gonadotrophs 
19
. 
 
Prolactin hormone: 
Prolactin hormone (PRL) is made  of a single polypeptide chain which 
containing about two hundred  amino acid residues and three disulfide bridges and has 
a considerable structural similarity to human growth hormone. The half-life of PRL, 
like that of growth hormone, is about 20 minutes
17
.PRL is secreted from the anterior 
pituitary and its target site of action is on the mammary glands. The main action of the 
prolactin hormone is the growth and induction of milk secretion during pregnancy and 
reaching a peak at paturation, PRL secretion is increased by stimulation of the nipples 
19
. 
Thyroid stimulating hormone: 
Thyroid stimulating hormone (TSH) is a glycoprotein which is of about 28 to 
30 KDa and is secreted from the anterior pituitary. It target site of action is on the 
thyroid follicular cells present in the thyroid gland
 19
. TRH in turn stimulates the 
anterior pituitary and leads to the secretion of the TSH, which inturn stimulates the 
release of T4 and T3.Secretion of thyroid-releasing hormone, and in turn the TSH, is 
inhibited by classical negative feedback loop mechanism. Free or unbound T3 and T4 
also play a important role by acting via this negative feedback mechanism by maintain 
the circulating thyroid hormone levels
 19
.  
Poly Cystic Ovarian Syndrome 
PCOS is a collection of spectrum of disorder with heterogeneous collection 
of signs  and symptoms which causes changes in the metabolic functions and 
Reproductive Endocrine in women. PCOS is characterized by irregular menstrual 
cycles or period of amenorrhoea with or without excess hair growth on face and 
body (Hirsutism), increase in weight, acene, thinning of the hair on the scalp and 
associated with ovarian cysts.  
The other factors associated with PCOS are obesity, type 2 diabetes, 
cardiovascular disease, and obstructive sleep apnoea, impaired fertility which 
increases the risk of diabetes, cardiovascular risk and endometrial cancer which 
are the short and long term complications of PCOS in women. In PCOS women 
the identity, mental health, and health related quality of life are becoming 
stigmatizing conditions 
22
. 
Prevalence : 
The prevalence of Poly Cystic Ovarian Syndrome was estimated to be about 
6.6% in adult women aged 18–45 years. However, the prevalence of PCOS was found 
to be higher in other countries than U.S   based on the diagnostic criteria.
15
 Estimated 
PCOS according to the phenotypes, morbidities and prevalence in associated with 
PCOS due to the lack of large-scale and epidemiological studies on PCOS 
23
. 
 The prevalence of other androgens excess disorder using the new 
diagnostic criteria suggested for diagnosis of PCOS and the most common classic 
feature of PCOS was androgen excess disorder which was about 30% of patients 
with clinical hyperandrogenism
24
. 
There is a necessity for estimation of proportion of women who are affected 
by PCOS in the population. Earlier studies support the percentage of 2.2-
2.6%.Using different available data of three different countries the prevalence is 
4.0-11.9%.but  in India there is paucity
25
.  
Clinical features of PCOS:   
The common clinical features of PCOS are Oligomenorrhoa and amenorrhoea 
are signs of anovulation and hirsutism is a sign of hyperandrogenism. Menstural 
cycles longer than 35 days or less than eight period of menstruation per year is applied 
for oligo/amenorrhoea. Hirsutism is  a sign of androgens excess being the underlying 
endocrine abnormality. In PCOS the presence of hirsute must be evaluated by clinical 
examination and other etiological abnormality must be excluded. Although hirsutism 
is a frequent feature in PCOS the identification of the etiology needs a systemic 
approach for evaluation and earlier management 
26
.The Ferriaman-Gallwey scoring 
was designed to assess the severity of hirsutism . 
The masculine pattern of body hair growth is described in four degrees on 
eleven different body parts; upper lip , chin ,lower back, chest upper back, lower 
abdomen, upper abdomen  , forearms, arms, thighs and the lower part of the legs. 
A score greater than 8 was considered hirsute
6
.Ovary and adrenal glands produce 
the androgens. Androgen excess which is the  hallmark feature of PCOS and 
contributor to the, stromal hyperplasia, antral follicle formation and 
hypervascularity and this  androgen excess which is necessary to measure the 
negative impact on fertility and sub fertility its regulatory benefits in  replacement 
with androgen therapy 
27
. 
Pathophysiology of PCOS: 
The pathophysiology for PCOS is multifactorial and polygenic .The phenotype 
of women with polycystic ovaries (PCO) and the polycystic ovarian syndrome is 
variable .In understanding the pathophysiology the nature of ovarian dysfunction has 
to be considered 
24
. 
There is uncertainty in considering the association of inappropriate 
gonadotrophin secretion that is LH and FSH in PCOS .Hence , twenty four hours 
pulsatile parameter for serum LH and pituitary gonadotrophin response to I.V 
bolus GnRH was given and the results showed that BMI does not influence 
gonadotrophin in normal cycling women. Taking LH levels and LH/FSH ratio 
along with BMI is considered beneficial
28
. 
It is indicated with higher androgen levels, increased prevalence of insulin 
resistance and more often CVD in first-degree relatives .The correlation of LH / 
FSH ratio, BMI and clinical manifestations of PCOS was conducted at institution 
of Infertility treatment and Embryo research. Iraq. The conclusion was negative 
and no significant correlation was found and the belief that obesity plays a role in 
pathophysiology   of PCOS which was a factor years back
29
. 
The   ovarian morphology is distinct and   pathogomonic for its major 
marker the hyperandrogenemia which is from the theca cells. The entire process 
from the follicular development to the period of primodial to pre-ovulatory is 
dependent on the gonadotropins. Polycystic ovaries of the anovulatory cycle had 
increased number of pre- antral follicle. This is thought to reduce the rate of 
recruitment from resting follicles. LH is considered to be the cause of 
hyperandrogenism of PCOS 
24
 
Along with steroidogenic enzymes in the synthesis of ovarian androgens 
.There is a possible explanation of the working mechanism of ovarian cautery by 
laparoscopy as a treatment in PCOS .They established that in PCOS there was 
thickened ovarian capsule along with dense hyperplastic ovarian stroma and 
multiple subcapsular cysts of the ovary
30
. 
In PCOS endocrine disorder associated with chronic anovulation ,an 
imbalance of LH and FSH results in abnormal estrogen and androgen production 
.The serum LH level is high and the serum FSH is low an altered  LH/FSH ratio is 
characteristic
31
.The combination of enlarged polycystic ovaries and obesity, 
oligomenorrhea and hirsutism shows an increased risk for the development of 
endometrial and possibly breast carcinoma
32
.There is large influence of genetic 
factors to the pathogenesis of PCOS and justified the search for the susceptibility 
of the gene location 
33
.  
Diagnosis of PCOS    
The Revised criteria of 2003 in diagnosing Polycystic Ovarian Syndrome 
based on the clinical or biochemical evidence of hyperandrogenism, chronic 
anovulation clinical trial showed that the evidence two out of the three criteria is 
necessary for the diagnosis
34, 5
. 
1. Oligo or amenorrhea 
2. Biochemical signs or clinical features of hyperandrogenemia 
3. transvaginal ultrasonography establishing  polycystic ovaries . 
There is a wide distribution of heterogenisity of signs and symptoms among 
women with PCOS and in some subjects PCOS can be expressed over time and can 
exist without clinical signs and symptoms at present. 
PCOS is prevalent in young Reproductive age group where the distribution is 
of  about 20-30%.
 
Polycystic ovaries have several times more primary, 
secondary and antral follicles compared to non-PCO women. The biological 
mechanisms behind PCOS was explained less, the condition behind this 
seems to be two-factorial. Mainly the intra-ovarian hyperandrogenism which 
leads to the early follicular growth promotion and leads to excess of follicle 
with of size 2-5 mm follicle. Studies have also revealed a positive correlation 
between follicle number and serum Testosterone/Androstendione 
concentration in PCOS women.  
A low aromatase activity due to an insufficient FSH stimulation affected by 
the synthesis of Estrogens which interferes the selection and growth of a dominant 
follicle Seconds the hyperandrogenism,. Insulin resistance, secondary to both 
genetic and lifestyle factors, is associated with anovulation, but probably not its 
primary cause.  
The ESHRE/ASRM sponsored for PCOS consensus workshop which was 
aimed for the diagnosis and the management of infertility publication in 2004, 
2008 respectively. They had discussions on hirsutism and acne include 
adolescence, the menstrual irregularities, the pregnancy complication, then on the 
contraception and quality of life, latter with long-term metabolic and 
cardiovascular health and cancer risks associated with  PCOS women.  
The  criteria needed for the diagnosis of PCOS which differ from 
adolescents to the reproductive age group women and the risk group with obesity, 
hirsute and irregular menses which should be classified and treated accordingly in 
a word of caution with over diagnosis in PCOS. The individual PCOS 
manifestation in adolescent should be taken in account and treated accordingly 
35
. 
The ovarian volume as the diagnostic criteria for PCOS included 154 
women with PCOS under NIH criteria as cases and 57 normal ovarian women as 
control. They concluded that ovarian volume 10 cm3 is a good diagnostic criteria 
for PCOS but even a threshold of 7cm3 with greater than 12 follicles appear to be 
a best diagnostic criteria and ovarian volume can be used as a surrogate for 
ovarian volume difficult situations
36
.  
Ovarian dysfunction: 
  Women of about  one-quarter and one-third of all women with anovulation 
or menstrual dysfunction have PCOS. The number of antral follicles increases in 
the ovaries lead to the risk of anovulation. In contrast, the number of ovulatory 
cycles increases if the number of antral follicles decreases, no matter if it is due to 
increased age (before menopause) or after ovarian parenchyma-reducing surgery . 
Women with PCOS usually have increased levels of luteinizing hormone (LH) 
relative to follicle stimulating hormone (FSH), i.e. the circulating LH to FSH ratio 
is elevated. The normal LH to FSH ratio which is 1:2 is altered to 2:1 or 3:1. This 
increase in the LH levels stimulates the theca cells to express the enzyme essential 
for the production of androgens to a higher extent, thus contributing to androgen 
excess. 
Also insulin stimulates theca cells to secret androgens. The accumulation of 
the antral follicle along with failure for the selection of the dominant follicle is the 
characteristic of PCOS .Oligoamenorrhea influence ovarian follicle in PCOS in 
two different ways .The sensitivity of the follicles to the FSH is excess and leads 
to more follicular development of small sized follicle 2-5mm diameter.  The 
selection of the dominat follicle form the follicular poll is lost which is under the 
influence of LH. This explains the follicular arrest in PCOS ovaries. 
The excessive stimulation of follicular cells by hormones insulin, LH, or 
both which contributes for the hyperandrogenism leading to follicular arrest, 
environment. However, exact mechanisms of follicular arrest are not fully 
understood.In PCOS women with oligo ovulation exhibit ovarian dysfunction in 
milder phenotype pattern compared to anovulatory and are favourable in response 
to the treatment with ovulation induction with clomiphine citrate. But in with 
recombinant FSH treatment the oligo ovulatory respond less than the anovulatory 
PCOS 
37
. 
Ultrasound description of polycystic ovary 
Transabdominal ultrasound is greatly replaced by transvaginal ultrasound. It 
was demonstrated that polycystic ovaries were defined as the presence of ≥10 cysts (2 
- 8mm diameter), ovarian volume ≥12cm3and bright ecogenic stroma(23 
book).Increased stroma echogenicity assessed transvaginally appeared to be 
exclusively associated with PCOS although this was a subjective appearance rather 
than a quantifiable measurement. Women with amenorrhoea had similar ultrasound 
features to those with oligomenorrhea.  
The appearance of polycystic ovaries is less important and there is a need to 
measure the follicular size in PCOS. Polycystic ovaries in premenopausal women  
are larger than the postmenopausal women.The multiple cysts in the ovary are, 
with a diameter of 4-10 mm and with normal echogenenicity  of the stroma 
38
. 
Although during puberty this is the characteristic appearance of the ovary and also 
in women recovering from the hypothalamic amenorrhoea- in the above situations 
it is the follicular growth which continues without recruitment of a dominant 
follicle. There is a need to differentiate between multicystic ovaries from 
polycystic ovaries for the diagnosis and proper management. 
In all young women immediately after menarche, irregular menses are 
common in these years. PCO is a common feature in women with irregular cycles 
when ultrasonography is done. There is no consensus of PCOS diagnostic criteria 
during adolescence, emphasizing a polycystic ovary from a multicystic or 
multifollicular. In adolescents, the ultrasonographic examination is often 
performed transabdominally, rather than transvaginally, even though the  
resolution is better transvaginally. This problem is further magnified by the 
inferior ultrasound resolution in obesity, and by the changes of ovarian 
findings with age . 
There was significant intra- observers and inter observer variability also 
using these criteria among inexperienced ultrasonographers, radiologists and 
gynaecologists, hence there is a need for careful consideration of clinical picture 
and  a supportive biomarker  in diagnosing PCOS
24
. 
The three dimensional ultrasound scanning and pulsed Doppler 
ultrasonography as a research tool in infertile women. In polycystic ovaries the 
measurement of ovarian stromal blood flow is a additional and useful parameter. 
The three- dimensional ultrasound technology can facilitate as a routine in clinical 
practice 
39
. In women undergoing IVF the prediction of ovarian reserve and antral 
follicular count is of paramount importance in predicting the outcome of 
pregnancy. The overall performance was assessed by a summary with ROC curve. 
Conclusion was that ovarian response was similar in the IVF patients with the use 
of one single test cannot be used in the assessment of ovarian volume
 40
.The stage 
of the disease and the management is largely based on ultrasound findings. 
Evaluation of ultrasound features of PCOS is dependent on the fact that experience 
of the specialist and necessary to standardize the description probability
41
. 
Reproductive consequence of PCOS 
 The most common cause PCOS is anovulatory cycles of infertility. In   
majority of women with PCOS anovulation, oligomenorrhoea or amenorrhoea is 
the main cause and it is due to the irregularities in the menstrual usually. This may 
be associated with  hyperandrogenism either  clinical and /or biochemical 
24
. 
Metabolic consequence of PCOS 
The condition “the diabetes of bearded women”is a disorder  associated 
with metabolism  of carbohydrate and  hyperandrogenism . In women with 
hyperandrogenism and diabetes mellitus skin lesion like acanthosis Nigerians 
frequently occurred .Additional features include the lipoatrophic diabetes 
syndromes, pineal hypertrophy, dental precocity, nails are thickened, and 
associated ovarian enlargement
42
.The metabolic evidence is there to justify the 
inclusion of both non- NIH group PCOS as Poly cystic ovarian subgroup in 
predicting the risk factor of CVD and T2DM 
43
.There is a strong genetic 
relationship to the etiology of PCOS. A considerable progress is made in 
identifying the susceptibility of gene and mapping studies with TGF- and insulin 
signalling, T2DM and obesity susceptibility 
44, 45
.A retrospective cohort study to 
show the effect of BMI on the outcome of patients with PCOS. Concluded that 
PCOS is a broad syndrome with obese and lean PCOS as two distinct population 
and have a difference in the IVF outcome and there is a need to differentiate them 
for the purpose of management and treatment in infertility 
46
. 
Anti Mullerian Hormone (AMH) 
Mullerian-inhibiting substance (MIS) was the initial name given for Anti-
Mullerian hormone (AMH)
 47.It
 is a glycoprotein and its molecular weight of AMH 
is of 140 kD. This belongs to a family of  Transforming growth factor β (TGF-β) 
.It is expressed in the gonads and has a main role in sex differentiation 
48,60
. During 
sex differentiation in the male foetus the AMH is expressed in the Sertoli cells. 
The testosterone is produced by the induction of the Müllerian ducts and the 
Leydig cells. The wolffian duct is diffentated into epididymis, Vas deference and 
the seminal vesicle. The absence of this hormone is responsible for the 
development of the female reproductive tract, which in turn leads to the 
differentiation of the mullerian duct into the oviduct, the uterus andthe upper part 
of the vagina in female foetus 
48
. Only from the 36 weeks of gestational age the 
AMH is, expressed in the ovary from long after the Müllerian ducts female foetus 
49,50
. The pre-antral and antral follicles produce AMH from the granulosa cells and 
involve in the follicular growth and development. Anti Mullerian Hormone in 
female serum is low at birth but later increase by puberty until adulthood and 
finally ceases at the period of menopause 
50, 51, 52
. 
The expression of AMH in the follicular fluid is highest in pre-antral and 
antral follicles sized 2-9 mm, followed by the stage of follicle growth through the 
next stages of follicle development and is lost in the FSH-dependent stages as well 
as in atretic follicles. The primodial follicle pool expresses AMH not from the 
dominant follicle or atresia cells.  
In granulosa cells the up regulation of AMH at the mRNA levels depending 
on the stages of development of the oocytes 
53
. The signalling pathway for AMH 
has been identified in the gonads and the gonadal cell lines. The main role of 
AMH on the follicle is inhibition of initial follicle recruitment and reduction of 
FSH sensitivity on the growing follicles
54, 55
. Remarkably few reports refers that 
AMH is a predictor of fecundity in women with normal fertility 
56
.  
AMH levels can predict the poor response in ART, and is unrelated to 
pregnancy outcome 
48, 57
. Serum AMH seems to represent a good quantitative 
measure of the ovarian pool of the primordial follicles, however, whether it 
represents a quality measure is less founded. Obviously, many aspects of AMH are 
still unknown and needs to be further explored. 
Several studies have recognized the connection between antral follicle 
count and AMH 
58, 59
.When the follicle-count diminishes less granulosa cells are 
available for production of AMH, which does not imply a direct relationship. As 
age advances there is a decrease in antral follicles and also decrease in both the 
levels of inhibin and sex steroids the reduced negative feedback acts in and leads 
to a rise in levels of serum Follicular Stimulating Hormone. Studies looking into 
the relationship between FSH and AMH under hormonal stimulation in women 
undergoing IVF. AMH shows a is in negative relationship between serum levels 
AMH and FSH .However, extension of the FSH-window that occurs during such 
gonadotropin-stimulation implies real supra-physiological levels of FSH over a 
prolonged time. 
This in turn, causes an increased recruitment of antral follicles with FSH-
induced accelerated growth that at a certain size looses their AMH expression. 
Hence, the AMH level must drop until a new cohort of follicles in line reach a 
stage where the AMH production again increases. For a limited amount of time, 
the amount of granulosa cells able to produce AMH is reduced
60
. 
Apart from the age-related decline in the AMH production, the ovarian 
production of this hormone is considered to be relatively stable during pregnancy. 
A few pre-reviewed papers concerning AMH levels in pregnancy have been 
published, including three cross sectional studies where one reported stable AMH 
levels without significant changes throughout the entire pregnancy and two 
revealed falling levels .A prospective longitudinal study reported a significant 
decline in AMH levels with advancing gestational length. 
This measurement would be useful to calculate the mean value, so the 
physician and their patients can consider the reproduction option 
61
.AMH is used 
to assess the ovarian reserve. So it can assess the relation declare of reproduction 
capacity 
62
. 
Based on the endocrinal of fetal sex differentiation the defect in androgen 
and AMH should be suspected if a patient is with ambiguous genitalia 
63
 AMH is 
confined to granuosa cells (GC) of primary follicles and is a marker fordiagnosis 
of ovarian tumour of GC origin.AMH level is found to be increased in 76-93% of 
the women with GC tumours. This extends upto the utility of detecting recurrence 
when elevation of AMH may occurs upto the monitoring period of 16 months 
64
. 
Traditionally, markers for hormonal dosage include demographic 
parameters, such as age, BMI, serum FSH and Inhibin B and ultrasound markers 
like antral follicle count and ovarian volume. A common problem connected to 
these markers has been a low sensitivity and specificity. During the last years 
papers have focused on AMH as an easy available marker for hormonal dosage in 
ART in infertility
65
. AMH has a specific role in the ovary and an indicator in 
women during and after the treatment cycles for cancer therapy 
66
. Evaluation of 
women in treatment and in successful outcome of assisted reproductive technology 
(ART) before planning treatment it in need to assess the ovarian reserve for good 
results and to decrease the cycle cancellation rate and the risk of ovarian hyper 
stimulation syndrome (OHSS) 
67
.   
There is still limited information regarding the use of AMH in a clinical 
setup. However a marker which reflects the severity of PCOS is them in need In 
the adolescent period where it is   rather difficult to diagnose PCOS by abdominal 
ultrasound. A marker which can aid in diagnosing the disease in need. This study 
will aid us to include the measurement of AMH in diagnosing PCOS subjects its 
role in the choice of the treatment and in further management 
 
 
 
 
Materials and Methods   
The present study is a case-control prospective study. The age   study 
population consisted of women aged between 18-40 years. The cases were newly 
diagnosed PCOS patients. The controls were healthy women having at least one 
healthy child. Those who attended the Obstetrics and Gynaecology OPD at 
Chennai medical college hospital and research centre. Irungalur. Trichy. 
 Period of the study  
Women 18 to 40 years old without history of other diseases at their visit 
between November 2013 to November 2014. Control women were selected from 
general population with healthy history and have at least one baby. Case and control 
women were matched for age.  
The inclusion criteria 
1. Menstrual cycle - regular (length of the cycle 25–35 days, 3-8 days duration of 
Menstruation) 
2. Medications on hormones should be avoided for 3 months. 
3. Should not be subjected to any surgical procedure in the reproductive system. 
4. Patients diagnosed as PCOS (By Rotterdam Criteria) 
Exclusion criteria                   
1. Post Menopausal  
2. Thyroid dysfunction 
3. Cushing syndrome 
4. Congenital adrenal hyperplasia 
5. Ovarian tumour 
6. Autoimmune disease 
Ethical considerations 
The researcher obtained the necessary approval to conduct the study from The 
Chennai Medical College Hospital and Research Centre college ethical committee. 
Irungalur Trichy. Women were explained about the purpose of this study and an 
informed written consent was obtained, confidentiality about their results was assured. 
Their participation was optional. 
Blood sample collection and storage: 
 About 5 ml blood sample were drawn from the median cubital vein from each 
woman on day three of the cycle or progesterone induced cycle into a plastic pyrogen 
-free disposable syringe. Transferred into a plastic tube and left for a 20 minutes to 
allow it to clot. After centrifugation at 3500 rpm for 10 minutes clear serum is 
obtained or stored at a -20°C until use. 
AMH, E2, FSH, LH, Ft3,Ft4 ,TSH, PRL and Total testosterone  analyses were 
carried out at the our central clinical Laboratory. 
 
 
A. BMI 
The body mass index (BMI) was determined by weight and height calculations 
using the following equation:  
                     BMI = Weight in Kg / Square of height in meters.    
According to Indian guidelines, a BMI from 23 to 24.9 is overweight, if the BMI 
is to be greater ≥ 25 is moderate obesity, and a BMI ≥ 30 is severe obesity. 
B.  Hirsutism 
Ferriman - Gallway score was used to assess the score for hirsutism , any score 
value >8 was considered to be positive and the presence of hirsutism is confirmed.  
C. Ultrasonography 
               Ultrasound analysis was performed using a trasvaginal US (TVUS) probe on 
each patient with a 6.5 MHz probe. In unmarried patients a trans abdominal 
ultrasound was performed.The ultrasound measurement was then obtained by a real- 
time B scan and was done by a  single physician according to the standardized 
protocol. 
A simple formula for prolate ellipse is 0.5XlengthXwidthXthickness was used 
to calculate ovarian volume. The average of the OV of both ovaries is defined as 
Ovarian volume per ovary.Antral follicular count was made by a 3 dimensional view 
and looking for follicle size and number in each dimension. 
 
 
 
Uterine size 
Uterine diameters are measured in the sagittal plane : maximum length from 
cervix to fundus X maximum anteroposterior diameter to provide the cross- sectional 
area. 
The follicle number 
The follicle number, size and total volume of ovary should be considered 
.Number of follicles per ovary or single slice of ovary in two diameters number ≥10 or 
≥12 or≥15 is considered polycystic. Normal ovaries do not have more than 9 follicles 
in number.  
Size of the follicle 
Follicle size 2-6, 2-8, >10mm are taken, as good discriminator between normal 
and polycystic ovaries .The mean diameter of ovarian volume and the number of 
follicles with a diameter of 2.0-8.0 mm were used for statistical analysis. 
D. Hormone assays 
1 . Antimullerian hormone assay 
AMH level was determined according to Durlinger et al. (1999) method using. 
UltraSensitive AMH/MIS ELISA AL-105-i 
     A. Principle of the assay 
1. AMH/MIS is a three-step sandwich  type immunoassay. 
2. The antibody-biotin conjugate binds solid phase of the antibody-antigen 
complex which then binds to the streptavidin-enzyme conjugate.  
3. The complex of antibody-antigen-biotin conjugate-SHRP is bound to the 
well and is then  detected by enzyme-substrate reaction.  
4. wavelength absorbance measurement at 450 nm as primary test filter and 
630 nm as reference filter  measures the  degree of enzymatic turnover of 
the substrate  
5. The absorbance measured is directly proportional to the concentration of 
AMH/MIS in the samples and calibrators. 
B. Kit components 
A 96 micro titration wells, Six  reference standard  0.05, 0.10, 0.25, 1.8, 7.5 and 
15 ng/ml  
Assay buffer , Wash buffer , diluting solution and the stopping solution. 
C. Procedure 
1. Micro titration strip was marked for use. 
2. Appropriate wells are taken and 20 μL of the standards, controls and samples 
were added. 
3. 100 μl of the MIS/AMH assay buffer were added  
4. The wells were incubated at 500-700 rpm and shaken at on an orbital 
5. Pattern in a micro plate shaker, for 1hour at room temperature (~25°C). 
6. Then each well was aspirated and washed 5 times for 30 seconds with the wash 
solution using an automatic microplate washer. The plate was inverted aeveral 
times on an absorbent material to make it dry. 
7. Using a precision pipette a 100 μl of the antibody-biotin conjugate solution 
were added into each well. 
8. For one hour at room temperature the wells were incubated and shaken at 500-
700 rpm on an micro plate shaker using a precision pipette each well was 
aspirated and washed 5 times for 30 seconds with wash solution using an 
automatic micro plate washer or manually 
9. To dry it the plate was inverted on an absorbent material using a precision 
pipette 100 μl of the streptavidin-enzyme conjugate-RTU were added into each 
well. 
10. Wells were incubated and shaken at 500-700 rpm on an orbital 
11. Micro plate shaker, for 30 minutes at room temperature (~25°C). 
12. Each well were aspirated and washed 5 times for 30 seconds with wash 
solution using an automatic microplate washer or manually using a precision 
pipette. Then the plate is dried using a precision pipette 100 μl of the TMB 
chromogen solution were added into each of the well. 
13. Then wells were incubated and shaken at 500-700 rpm on an orbital microplate 
shaker, for 10-15 minutes at room temperature (~25°C)  
14.  100 μl of the stopping solution were added into each well using a precision 
pipette. 
15. The absorbance of the solution in each well was read within 30 minutes, at 450 
nm (450-620nm). 
D. observation and results 
The absorbance for each control, standard,  or sample was obtained , and then a 
standard curve was prepared by plotting the absorbance readings for each of the 
standards along the Y-axis versus MIS/AMH concentrations in ng/mL along the X-
axis, using a linear curve-fit. The MIS/AMH concentrations of the samples were 
determined from thestandard curve by matching their mean absorbance readings with 
the corresponding MIS/AMH concentrations. 
Reference values of AMH in adult females 
The range of this hormone on the 3
rd
 day of menstrual cycle is 2.0-6.8 ng/dl . 
1. Testosterone assay:- Testosterone Test System Product Code:   3725-300 
PRINCIPLE: Competitive Enzyme immunoassay (TYPE 7): 
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conc. of AMH (ng/mL) 
 The essential reagent required for a enzyme immunoassay include antibody, 
enzyme-antigen conjugate native antigen, Upon mixing biotinylated antibody, 
enzyme-antigen conjugate and a serum containing the native antigen, a competition 
reaction result between the native antigen and the enzyme-antigen conjugate for a 
limited number of antibody binding sites, The interaction illustrated  by the followed 
equation. 
  
Enz
 Ag + Ag +Ab Btn    ka   Ag AbBtn + 
Enz 
Ag AbBtn 
        ka                                                           
Ab Btn  =  Biotinylated Antibody  
Ag  = Native Antigen   
Enz Ag = Enzyme-antigen conjugate  
Ag Ab Btn = the Antigen-Antibody complex 
Enz
 Ag Ab Btn = Enzyme-antigen conjugate-Antibody complex 
Ka = Rate constant of the Association 
k-a = Rate constant of the Disassociation 
K=ka/k-a = Equilibrium Constant 
On the microwell a simultaneous reaction between the biotin antibody and the 
streptavidin immobilized occurs. After the  aspiration it effects the separation of 
the antibody bound fraction  
AgAbBtn + 
Enz 
AgAbBtn + Streptavidin  cw → immobilized complex   
 streptavidin cw  = streptavidin immobilized on well  
Immobilized complex  = sandwich complex bound to the solid surface. 
The enzyme activity which is in the antibody bound fraction is inversely 
proportional to the native antigen concentration 
REAGENTS 
A. Testosterone calibrators- 1ml/vial-icons A-G , serum reference for Testosterone 
at  concentrations of 0 (A) 0.1 (B), 0.5 (C), 1.0 (D),2.5 (E), 5.0 (F) and 12.0 (G) 
in ng/ml  
B. Testosterone Enzyme Reagent -1.0 ml/vial E - Testosterone (Analog) 
horseradish peroxides (HRP) conjugate ,  
C. Steroid conjugate Buffer -7.0 ml  
D. Testosterone Biotin Reagent -6.0 ml-anti-Testosterone biotinylated purified 
rabbit lgG conjuagate in buffer,  
E. Steptavidin coated plate -96 wells –One  96-well microplate coated with 1.0 
ug/ml steptavidin Wash solution concentrate-20ml 
F. Substrate A -7ml/ tetramethyl benzidine (TMB) in buffer.  
G. Substrate B – 7ml/ vial –hydrogen peroxide (H2 O2 ) in buffer . 
H. Stop solution – 8ml/vial-a strong acid (1N HCI).  
PROCEDURE 
1. Control and patient specimen are formatted in microplates wells for each serum 
reference to be assayed in duplicate. 
2. In the assigned well Pipette 0.010ml (10ml) of the appropriate serum reference 
control or specimen. 
3. Testosterone Enzyme Reagent of  0.050 ml (50ul) is added to all the well for  20-
30 seconds Swirl the microplate gently  
4. To all wells add Testosterone  Biotin Reagent of  0.050 ml (50ul) for 20-30 
seconds to mix Swirl the microplate .  
5. At room temperature cover and then incubate for one hour. 
6. Aspirate the content of microplate and discard and with absorbent paper blot the 
plate dry.  
7. Add 350ul of wash buffer and aspirate. Repeat the same for two times for a total 
up to three wash.  
8. To all wells add 0.100 ml (100ml) of working substrate at room temperature 
incubate for 15 minutes. 
9. Stop solution of 0.050ml (50ul) is added of to each well. Mix for 15-20 seconds. 
10. Read  the  absorbance  in each well at 450nm  
RESULTS. 
Absorbance for each standard, control, or sample was obtained, and then a 
standard curve was prepared by plotting the absorbance values for each of the 
standards along the Y-axis versus the X-axis the standard concentrations in pg/ml. A 
best-fit curve connecting the points is done. The mean absorbance value estimated for 
each sample using the corresponding   concentration of testosterone ng/dl from the 
standard curve 
Reference range values of the Testosterone in adult females:  
The normal range of Testosterone during the early follicular phase in adult 
females is between 15.0 – 80.0 ng/dl 
3. Estradiol assay 
 Estradiol  (E2)  Test  Systems Code of the Product   :   4925-300 
PRINCIPLE 
Delayed Competitive Enzyme linked Immunoassay  
The biotinylated Antibody with a serum containing the antigen, a reaction 
results between the antigen and the antibody. The interaction is illustrated by the 
following equation 
   
Ag + AbBtn 
                               
Ag AbBtn
 
 Ab =  Biotinylated antibody 
Ag  = Antigen  
AgAb  = the Immune Complex 
The  enzyme conjugate is added After a short incubation. Upon the addition of 
the enzyme conjugate, competition reaction results between the enzyme analog 
and the antigen in the sample for a limited number of antibody binging sites ( not 
consumed in the first incubation). 
          
Enz
Ag   +    Ag +  rAbBtn       Ka    Ag AbBtn   +    
ENZ
AgAbBtn 
                                                       K –a 
Enz Ag b=  Enzyme-antigen Conjugate (Constant Quantity) 
Enz Ag Ab = Enzyme-antigen Conjugate-Antibody Complex 
Ab Btn = Biotinylated antibody not reacted in first incubation 
K a   = Rate Constant of Association 
K-a   = Rate Constant of Disassociation 
K = Ka/ ka = Equilibrium Constant 
After aspiration.Streptavidin is  immobilized on the microwell this effects the 
separation of the antibody bound fractions.  
AgAbBtn  +
ENZ
 AgAbBtn     + Streptavidin                      the Immobilized complex 
Streptavidin   = Streptavidin immobilized on the  well; 
Immobilized  complex  =   Sandwich complex   bound to the solid surface 
The enzyme activity in the antibody bound fraction is inversely proportional to 
the native antigen concentration.   
 
REAGENTS 
A. Estradiol Calibrators  -1ml  . 
B. Add the Reference serum for estradiol at concentration of 0 (A), 20  (B), 100 
(C), 250 (D), 500 (E), 1500 (F) and 3000 (G) in pg/ml.   
C. Estradiol Enzyme Reagent  -6.0 ml horseradish peroxides (HRP)  
D. Estradiol Bioting Reagent -6.0 ml -anti-estradiol biotinylated purified rabbit lgG  
E. 96 Wells Streptavidin Coated Plates  Each well is coated with 1.0 ng/ml strep 
avidin. 
F. Wash solution -20ml 
G. Substrate Reagent – 12ml -teramethylbenzidine  (TMB) and hydrogen peroxide 
(H2 O2) in buffer  
H. Stop Solution -8 ml of strong acid (H2 SO4) store at 2.30 C 
 
 
PROCEDURE 
1. Serum reference control or specimenof about 0.025 ml (25ul) is  Pipetted into 
the well. 
2. Estradiol Biotin Reagent of 0.050 ml (50ul) is added. 
3. For 20-30 seconds to mix swirl the microplate  gently.  
4. At room temperature incubate after Covering  for half hour. 
5. Estradiol Enzyme Reagent of 0.050 ml (50ul) is added  in the wells. 
6. For 20-30 seconds swirl the microplate gently to mix at room temperature Cover 
and incubate for 1 hour and 30 mins. 
7. Aspirate the content of the microplate and discard  
8. With absorbent paper blot the plate dry. 
10. Add 350μl of wash buffer  -aspirate the content Repeatby three additional times. 
11. Add 0.050ml (100ul) of substrate solution to all  
12. Incubate at room temperature for twenty (20) minutes 
13. Add 0.050ml (50ul) of stop solution to each well  
The absorbance is read in each well at 450nm  
RESULTS: 
Absorbance for the control, standard, or sample was obtained. by plotting the 
absorbance readings a standard curve was prepared for each of the standards plotting 
the standard concentrations in pg/ml along the X-axis and absorbance reading along 
the Y-axis . Connect the best of the points. From the standard curve the mean 
absorbance of the value for each of the sample was used to determine the 
concentration of estradiol in pg/ml  
 
E. Reference value of E2 in adult females 
The normal range of these hormones in adult females during early follicular 
phase is between 25-100 pg/ml 
4. Follicles Stimulating Hormone assay 
The Follicles Stimulating Hormone (FSH) Product Code   425-300 
PRINCIPLE 
The Immuno enzymometric assay method   
 The immobilization of the antibody takes place during the assay at the surface 
of a  microplate well by the interaction of the biotinylated monoclonal anti-FSH 
antibody and the streptavidin coated well.  They form a soluble sandwich antigen 
antibody complex.   
The interaction is illustrated by the following equation   
  
Enz 
Ab(p)  + Ag  +  
Btn 
Ab  (m)      Ka         
Enz
 Ab(p)  –AgFSH  -   
Btn
 Ab(m)                                                                                           
                                                  K-a 
   Ab  =  Biotinylated Monoclonal Antibody   
 Ag    = the Native Antigen 
 Enz Ab = Enzyme labeled Antibody  
 Enz ABb = gfsh  Ab  =  Antigen –Antibodies sandwich compiled 
 k-a         =   Rate Constant of Association 
 k-a       =   Rate Constant of Dissociation 
streptavidin and biotinylated antibody complex is deposited to the well through 
the high affinity reaction .This interaction is illustrated below. 
Enz Ab  gfsh = Ab + Streptavidin  =Immobilized complex 
Streptavidin = Streptavidin immobilized on well 
Immobilized complex = sandwich complex bound to the solid surface. 
After aspiration, the antibody-bound fraction is separated from unbound antigen. 
The enzyme activity in the antibody-bound fraction is directly proportional to the 
native antigen concentration.   
REAGENTS;- Materials Provided:   
1. FSH Calibrators -1 ml 
FSH Antigen at levels of 0 (A) 5 (B), 0 (C), 25(D), 50(E) and 100 (F)  
2. FSH Enzyme Reagent – 13 ml -enzyme labloed antibody, biotinylated 
monoclonal mouse lgG  
3. Streptavidin Coated Plate -96 wells  
4. Wash solution concentrate -20 ml 
5. Substrate A – 7.0 ml-  tetramethylbenzidine  (TMB) in buffer 
6. Substrate B -7.0 ml- hydrogen peroxide (H2,O2)  
7. Stop solution – 8ml- strong acid (1N HCI)  
PROCEDURE 
 1. Appropriate serum reference control is pipetted of about 0.050 ml (50ul) of 
into the assigned well. 
2. FSH-Enzyme Reagent solution of 0.100ml (100ul) is added to all wells. 
3. For 20-30 seconds to mix then swirl in the microplate. 
4. At room temperature incubate 1 hour. 
5. Aspirate the content and dry the microplate. 
6. Add 350ul of wash buffer and repeat the procedure 3 times. 
7. Working substrate solution of 0.100 ml (100ul) is added to all wells  
         8. Incubate at room temperature for fifteen (15) minutes. 
9.Add 0.050 ml (50ul)  of stop solution to each well and gently mix for 15-20 
seconds 
10. Read the absorbance in each, well at 450nm  
 
RESULTS 
Absorbance for the control, standard, or sample was obtained. by plotting the 
absorbance readings a standard curve was prepared for each of the standards plotting 
the standard concentrations in pg/ml along the X-axis and absorbance reading along 
the Y-axis . Connect the best of the points. From the standard curve the mean 
absorbance of the value for each of the sample was used to determine the 
concentration of FSH in IU/ml from the standard curve. 
E. Reference values of FSH in adult females 
The normal range of Follicle stimulating hormones in adult females during 
early follicular phase is between 1.4- 9.9 mIU/mL 
5. Luteinizing Hormone assay 
Luteinizing Hormone (LH) Code of the Product:  625 -300 
PRINCIPLE 
Immuno enzymometric assay. The biotinylated monoclonal anti-LH antibody is 
added to the streptavidin in the microplate .Upon mixing monoclonal biotinylated 
antibody, the enzyme labelled antibody a soluble sandwich complex is formed.  The 
interaction is illustrated by the following equation.  
Enz
 Ab(p)   +Ag LH + 
Btn
Ab(m)    k -a   
 Enz
 Ab (p)  – Ag LH  -  
Btn
Ab(m)                                              
   K -a 
Ab  =  Biotinylated Monoclonal Antibody  
Ag  = Native Antigen  
Enz Ab = Enzyme labeled Antibody  
Enz Ab-Ag-Ab = Antigen- Antibodies sandwich Complex 
k-a   =  the  rate constant of Association 
k-a   =  the rate Constant of Dissociation 
Streptavidin and  biotinylated antibody the complex is deposited to the well. This 
interaction is illustrated below. 
Enz Ab – Ag –Ab  +   Streptavidin =  Immobilized complex 
Streptavidin     =    Streptavidin immobilized on well 
Immobilized complex =  Antibodies –Antigen sandwich bound 
 Aspiration,  the antibody-bound fraction is separated from the unbound antigen. 
The enzyme activity in the antibody-bound fraction is directly proportional to the 
native antigen concentration.   
REAGENTS 
LH Calibrators- 1ml -LH Antigen at levels of  0(A), 5 (B), 25(C), 50 (D), 100 
(E) and 200 (F)mlU/ml. 
A. LH Enzyme Reagent -13 ml - enzyme labelled affinity purified antibody, 
biotinylated  monoclonal  mouse lgG. 
B. Streptavidin coated plate -96 wells. 
C. Wash solution concentrate -20 ml.  
D. Substrate A – 7 ml- tetramethyl benzidine (TMB) in buffer. 
E. Substrate B -7 ml -hydrogen peroxide (H2 O2) in buffer.  
F. Stop solution -  8ml - strong acid (1N HCI). 
PROCEDURE     
1. serum reference, control and patient  specimen in a micro plate wells.  
2. Pipette 0.050 ml (50ul) of the appropriate serum reference, control or specimen 
into the assigned well. 
3. Add 0.00ml (100ul) of LH-Enzyme Reagent.  
4. 20-30 seconds Swirl the micro plate.  
5. At room temperature incubate for 1 hour. 
6. Aspirate the microplate and discard the content dry the microplate. 
7.  Add 350ul of wash buffer for a total of 3 washes. 
8. Working substrate solution of 0.00ml (100ul) is added to the well. 
9.  At room temperature incubate for fifteen minutes. 
10. Stop solution of 0.050ml is added and gently mixed for 15- 20 seconds.   
11.  Read  the absorbance in each well at 450nm  
 
RESULTS. 
Absorbance for the control, standard, or sample was obtained. by plotting the 
absorbance readings a standard curve was prepared for each of the standards 
plotting the standard concentrations in pg/ml along the X-axis and absorbance 
reading along the Y-axis . Connect the best of the points. From the standard curve 
the mean absorbance of the value for each of the sample was used to determine the 
concentration of LH in IU/ml from the standard curve                        
E. Reference values of LH in adult females 
The normal range of Luteinizing hormone in adult females during early follicular 
phase is between 1.7 - 15 mIU/ml 
6. Prolactin Hormone assay 
THE Prolactin Hormone (PRL) Code of the  Product : 725-300                           
PRINCIPLE 
Immunoenzymometric assay (TYPE 3): 
The streptavidin coated on the well and biotinylated monoclonal anti– PRL antibody 
is added. A soluble sandwich complex is formed by mixing monoclonal biotinylated 
antibody, and the enzyme labelled antibody and a serum containing the native antigen 
reaction results between the native antigen and the antibodies.  The interaction is 
illustrated by the following equation. 
Enz
  Ab (P)  +Ag PRL  +  
Btn
 Ab(m)      ka   
Enz
  Ab (P)    --  Ag PRL  - 
Btn
 Ab(m)                                            
k-a   
Ab            =  Biotinylated  Monoclonal Antibody   
Enz Ab     = the Native Antigen   
Enz Ab    = the Enzyme labelled Antibody  
Enz  Ab  -Ag    -Ab  = Antigen – Antibodies Sandwich Complex 
K – a   = the  Rate Constant of Association 
K – a   =  the Rate Constant of Dissociation 
Simultaneously, the complex of streptavidin and biotinylated antibody is deposited to 
the well. This interaction is illustrated below. 
Enz Ab  -  Ag --  Ab +  Streptavidin  = immobilized complex 
Streptavidin  =  Streptavidin immobilized on well 
Immobilized complex = Sandwich complex bound to the well. 
After equilibrium is attained, the antibody – bound fraction is separated from unbound 
antigen by decantation of aspiration 
REAGENTS 
A. PRL Calibrators -  1 ml - PRL antigen in human serum at levels of  0(A), 5(B),  
10(C),  25(D),  50(E),  and 100 (F) ng/ml  
B. PRL Enzyme –Reagent – 13ml - enzyme labelled antibody, biotinylated 
monoclonal mouse igG  
C.  Streptavidin Coated Plate – 96 wells  
D. Wash solution concentrate -20 ml  
E. Substrate   A – 7ml - tetramethylbenzidine (TMB) in buffer  
F. Substrate B- 7ml - hydrogen peroxide (H2,O2) in buffer. 
G. Stop solute on – 8ml -a strong acid (1N HCI). 
PROCEDURE 
1. Format the microplate wells for each serum reference control and patient 
specimen.  
2. Pipette 0.025 ml (25ul) of the appropriate serum reference control or specimen 
into the assigned well. 
3. PRL Enzyme Reagent solution of 0.100 ml (100ul) added to the wells. 
4. For 20-30 seconds swirls the microplate gently.At room temperature incubate 1 
hour.  
5. Aspirate the microplate and discard and dry the plot by absorbent paper. 
6.  Add 350ul of wash buffer  and repeat the procedure for 3 wash 
7. Working substrate solution of 0.100 ml (100ul) is added. 
8. At room temperature incubate for fifteen (15) minutes 
9. Stop solution of 0.050ml (50ul) is added and mix for 15-20 seconds 
10. Read the absorbance in each well at 450nm  
E. Reference values of PRL in adult females 
The normal range of Prolactin hormones in adult females in early follicular phase is 
between 0.9- 25 mIU/ml. 
 
 
 
 
 
 
 
 
 
 
 
 
 Results and statistics 
 
Age group 
Cases  
N (%) 
Controls  
N (%) 
Total 
N (%) 
<20 years 3 (10) 3 (10) 6 (20) 
21- 30 years 18 (60) 18 (60) 36 (60) 
31 - 40 years 9 (30) 9 (30) 18 (30) 
Total 30 (100) 30 (100) 60 (100) 
 
Mean age: 28.63 years 
Standard deviation: 5.64 years 
 Minimum: 18 years 
Maximum: 40 years 
Table 1 Age distribution of the study population (n=60) 
 
 
 
 
  
 
Age distribution 
 
 
 
 
Figure 1: Age distribution of the study population (n=60) 
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Comparison of age 
Student “t” test 
 
Group Mean Age Std. Deviation 
Mean 
difference 
p value 
95% confidence 
interval 
Cases 
(30) 
28.50 5.625 
-0.267 0.857 -3.210 to 2.677 
Controls 
(30) 
28.77 5.764 
 
Subjects in the Cases group were not so different from subjects in control 
group with the mean age difference being 0.267 and this mean difference was not 
statistically significant. Hence both the cases and controls were comparable in terms 
of age. 
 
Table 2 Comparison of age among cases and controls (n=60) 
 
 
 
  
 
 
 
 
 
Figure 2: Box plot comparison of age among cases and controls (n=60) 
 
 
 
  
Comparison of LH hormone levels (mIU/ml) 
Student “t” test 
 
Group 
Mean LH 
(mIU/ml) 
Std. Deviation 
Mean 
difference 
p value 
95% confidence 
interval 
Cases (30) 10.60 3.24 
    3.21 0.001* 1.299 to 5.120 
Controls (30) 7.39 4.10 
 
*statistically significant at 0.05 level 
  Subjects in the Cases group had a mean LH level of around 10mIU/ml while 
subjects in control group had a mean LH level of around 7mIU/ml and this mean 
difference was statistically significant.  
Table 3: Comparison of LH hormone levels (mIU/ml) among cases and 
controls (n=60) 
 
 
 
  
 
 
 
Figure 3: Box plot comparison of LH hormone levels (mIU/ml) among cases 
and controls (n=60) 
 
 
 
 
 
 
  
Comparison of FSH hormone levels (mIU/ml) 
  
Student “t” test 
 
Group 
Mean FSH 
(mIU/ml) 
Std. 
Deviation 
Mean 
difference 
p value 
95% confidence 
interval 
  Cases 
           (30) 
5.60 1.99 
0.059 0.925 -1.191 to 1.309 
Controls 
(30) 
5.54 2.78 
 
The difference in mean FSH levels between cases and controls was very 
minimal of about 0.06 mIU/ml and this mean difference was not statistically 
significant.  
Table 4 Comparison of FSH hormone levels (mIU/ml) among cases and 
controls (n=60) 
 
 
 
  
 
 
 
 
Figure 4: Box plot comparison of FSH hormone levels (mIU/ml)   among 
cases and controls (n=60) 
 
 
 
 
 
 
 Comparison of Testosterone levels (ng/ml) 
Student “t” test 
 
Group 
Mean 
testosterone 
(ng/ml) 
 
Std. 
Deviation 
Mean 
difference 
p value 
95% confidence 
interval 
Cases (30) 73.02 19.43 
23.07 <0.001* 14.48 to 31.66 
Controls (30) 49.94 13.21 
 
*statistically significant at 0.05 level 
Subjects in the Cases group had a mean testosterone level of around 73ng/ml 
and subjects in control group had a mean testosterone level of around 50ng/ml and this 
mean difference was statistically significant. 
 
Table 5 Comparison of Testosterone levels (ng/ml) among cases and 
controls (n=60) 
 
 
  
 
 
 
 
Figure 5: Box plot comparison of testosterone (ng/ml ) and Estradiol 
hormone levels (pg/ml )among cases and controls (n=60) 
 
 
 
 
 
  
Comparison of E2 level (pg/ml ) 
 
Student “t” test 
 
Group 
E2 level 
(pg/ml ) 
Std. 
Deviation 
Mean 
difference 
p value 
95% confidence 
interval 
Cases 
(30) 
71.18 
10.8
8 
-2.51 0.409 -8.57 to 3.54 
Controls 
(30) 
73.70 
12.5
0 
 
Subjects with PCOS had a mean estrogen (E2) level of 71 units and subjects in 
control group had a mean level of around 73 units and this mean difference was not 
statistically significant. 
 
Table 6 Comparison of E2 level (pg/ml ) among cases and controls (n=60) 
 
 
 
 Comparison of Prolactin levels (ng/ml) 
Student “t” test 
 
Group 
Mean 
prolactin 
(ng/ml) 
Std. 
Deviation 
Mean 
difference 
p value 
95% confidence 
interval 
Case 
s (30) 
12.57 5.29  
     3.39 0.007* 5.82 to 0.95 
Controls 
(30) 
9.18 4.04 
 
*statistically significant at 0.05 level 
Subjects in the Cases group had a mean prolactin hormone level of around 
12ng/ml and subjects in control group had a mean level of around 9ng/ml and this 
mean difference was statistically significant. 
 
Table 7 Comparison of Prolactin levels (ng/ml) among cases and controls 
(n=60) 
 
 
 Comparison of total antral follicular count 
Student “t” test 
 
Group 
Combined 
mean AFC  
Std. 
Deviation 
Mean 
difference 
p value 
95% 
confidence 
interval 
Cases 
(30) 
30.20 3.36 
22.0 <0.001* 
20.536 to 
23.464 Controls 
(30) 
8.20 1.62 
 
*statistically significant at 0.05 level 
 
Subjects in the Cases group had a mean combined antral follicular count of 
around 30 and subjects in control group had a mean level of around 8 and this mean 
difference was statistically significant. 
 
Table 8 Comparison of total antral follicular count (combined AFC of both right 
and left ovaries) among cases and controls (n=60) 
 
 
 Comparison of average ovarian volume (cm
3
) 
Student “t” test 
 
 
Average 
ovarian 
Volume 
(cm
3
) 
Std. 
Deviation 
Mean 
difference 
p value 
95% confidence 
interval 
Cases (30) 15.13 2.67 
9.99 <0.001* 8.96 to 11.03 
Controls(30) 5.14 0.87 
 
*statistically significant at 0.05 level 
Subjects with PCOS had a average ovarian volume of around 15cm
3
 and 
subjects in control group had a average ovarian volume of around 5cm
3
 and this mean 
difference was statistically significant. 
 
Table 9 Comparison of average ovarian volume (cm
3
) among cases and 
controls (n=60) 
 
 
  
 
 
 
Figure 6: Box plot comparison of antral follicular count and average ovarian 
volume (cm
3
) among cases and controls (n=60) 
 
 
 
 
 
 
 
 Comparison of body mass index (BMI) (kg/m
2
) 
Student “t” test 
 
Group 
BMI 
(kg/m
2
) 
Std. 
Deviation 
Mean 
difference 
p value 
95% confidence 
interval 
Cases (30) 28.46 4.78 
2.94 0.031* 0.272 to 5.610 
Controls (30) 25.52 5.51 
 
*statistically significant at 0.05 level 
   Subjects with PCOS had a BMI of around 28 kg/m
2
 and subjects in control 
group had a mean level of around 25 kg/m
2
 and this mean difference was statistically 
significant. 
 
Table 10 Comparison of body mass index (BMI) (kg/m
2
) among cases and 
controls (n=60) 
 
 Comparison  of  anti-mullerian hormone  (AMH)  levels  (ng/ml) 
 
Student “t” test 
Group 
Mean AMH 
     (ng/ml) 
Std. 
Deviation 
Mean 
differenc
e 
(ng/ml) 
p value 
95% 
confidence 
interval 
Cases (30) 11.28 5.29 
7.62 <0.001* 5.58 to 9.66 
Controls 
(30) 
3.65 1.46 
 
*statistically significant at 0.05 level 
Subjects in the Cases group had a mean anti-mullerian hormone level of around 
11ng/ml and subjects in control group in case the mean level of AMH  was around 
3ng/ml and this mean difference was statistically significant. 
 
Table 11 Comparison of anti-mullerian hormone (AMH) levels (ng/ml) 
among cases and controls (n=60) 
 
 
  
 
 
Figure 7: Box plot comparison of anti-mullerian hormone levels (ng/ml) 
among cases and controls (n=60) 
 
 
 
 
 Correlation between AMH levels(ng/ml) and Age 
 
Group 
Pearson 
correlation  
p value 
Cases (30) -0.270 0.149 
Controls (30) -0.536 0.002* 
 
*statistically significant at 0.05 level  
In subjects with PCOS, AMH levels had a negative relationship with age but 
there was no correlation and was not statistically significant while AMH levels in 
control subjects had a negative linear relationship was statistically significant with 
age. i,e. As age increases in control subjects, AMH level tend to decrease.   
 
Table 12 Correlation between AMH levels(ng/ml) and Age distribution 
among cases and controls (n=60) 
 
 
 
  
 
 
 
 
Figure 8: Scatter plot comparison of anti-mullerian hormone levels and age 
among cases and controls (n=60) 
 
 
 
 
 Correlation between AMH levels (ng/ml) and LH (mIU/ml levels 
 
Group 
Pearson 
correlation  
p value 
Cases (30) -0.335 0.071 
Controls (30) 0.449 0.013* 
 
*statistically significant at 0.05 level 
 
In subjects with PCOS, AMH levels had a negative relationship and was not 
statistically significant with LH levels .AMH levels in control subjects had a positive 
linear relationship with LH levels and this correlation was statistically significant. i,e. 
As LH levels increases in control subjects there is a corresponding increase in AMH 
levels and vice versa.   
 
Table 13: Correlation between AMH levels (ng/ml) and LH (mIU/ml levels 
among cases and controls (n=60) 
 
 
 
  
 
 
 
Figure 9: Scatter plot comparison of anti-mullerian hormone levels (ng/ml) 
and LH levels (mIU/ml) among cases and controls (n=60) 
 
 
 
  
Correlation between AMH (ng/ml) levels and FSH (mIU/ml) levels 
 
 
Group 
Pearson 
correlation  
p value 
Cases (30) -0.375 0.041* 
Controls (30) -0.139 0.463 
 
*statistically significant at 0.05 level 
In subjects with PCOS, AMH levels had a negative linear relationship with 
FSH levels but this correlation was statistically significant while AMH levels in 
control subjects also had a negative linear relationship with FSH levels but this 
correlation was not statistically significant. i,e. As FSH levels increases in PCOS 
subjects there is a corresponding decrease in AMH levels and vice versa.   
 
Table 14 Correlation between AMH (ng/ml) levels and FSH (mIU/ml) levels 
among cases and controls (n=60) 
 
 
 
  
 
 
Figure 10: Scatter plot comparison of anti-mullerian hormone levels and FSH 
levels (mIU/ml) among cases and controls (n=60) 
 
 
 
 
 Correlation between AMH levels(ng/ml) and testosterone 
 
Group 
Pearson 
correlation  
p value 
Cases (30) -0.133 0.485 
Controls (30) -0.328 0.077 
 
In both subjects with PCOS and control subjects, AMH levels had a negative 
linear relationship with testosterone levels but this correlation was not statistically 
significant.   
 
Table 15 Correlation between AMH levels(ng/ml) and testosterone 
levels(ng/ml) among cases and controls (n=60) 
 
 
 
 
 
  
 
 
Figure 11: Scatter plot comparison of anti-mullerian hormone levels and 
testosterone levels among cases and controls (n=60) 
 
 
 
 
 
  
Correlation between AMH levels (ng/ml)and combined antral 
follicular count 
Group 
Mean 
combined AFC 
Standard 
deviation 
Pearson 
correlation 
p value 
Cases (30) 30.20 3.662 0.562 
0.001
* 
Controls 
(30) 
8.20 1.627 0.328 0.077 
 
*statistically significant at 0.05 level 
 
In subjects with PCOS, AMH levels had a positive linear relationship with 
combined antral follicular count and this correlation was statistically significant while 
AMH levels in control subjects also had a positive linear relationship with combined 
antral follicular count but this correlation was not statistically significant. i,e. As 
AMH levels are increased in PCOS subjects with high antral follicular count and vice 
versa.   
Table 16 Correlation between AMH levels (ng/ml)and combined antral 
follicular count in both ovaries among cases and controls (n=60) 
 
 
  
 
 
 
 
Figure 12: Scatter plot comparison of anti-mullerian hormone levels (ng/ml) 
and combined antral follicular count among cases and controls (n=60) 
 
 
 
  
Correlation between AMH levels (ng/ml) and combined ovarian volume 
 
Group 
Mean 
combined 
ovarian 
volume 
        (cm
3
) 
Standard 
deviation 
Pearson 
correlation 
p value 
Cases 
(30) 
30.27 5.34 0.572 
0.001
* 
Controls 
(30) 
10.28 1.75 0.244 0.193 
 
*statistically significant at 0.05 level 
 
In subjects with PCOS, AMH levels had a positive linear relationship 
with combined ovarian volume and this correlation was statistically significant 
while AMH levels in control subjects also had a positive linear relationship with 
combined ovarian volume but this correlation was not statistically significant. 
i,e. As AMH levels are increased in PCOS subjects with high combined ovarian 
volume and vice versa.   
Table 17 Correlation between AMH levels (ng/ml) and combined ovarian 
volume (both ovaries) (cm
3
) among cases and controls (n=60) 
 
  
 
 
 
 
 
 
Figure 13: Scatter plot comparison of anti-mullerian hormone levels (ng/ml) 
and combined ovarian volume among cases and controls (n=60) 
 
 
 
 Correlation between AMH levels (ng/ml) 
and body mass index(Kg/m
2
 ) 
 
Group 
Mean BMI 
(Kg/ m
2
 ) 
Standard 
deviation 
Pearson 
correlation 
p value 
Cases (30) 28.46 478 0.080 0.674 
Controls (30) 25.52 5.51 -0.018 0.925 
 
 
In subjects with PCOS, AMH levels had a positive linear relationship 
with BMI but this correlation was not statistically significant while AMH levels 
in control subjects had a negative linear relationship with BMI but this 
correlation was also not statistically significant. 
 
Table 18: Correlation between AMH levels (ng/ml)and body mass 
index(Kg/m
2
 ) among cases and controls (n=60) 
 
 
  
 
 
 
 
Figure 14: Scatter plot comparison of anti-mullerian hormone levels and 
body mass index kg /m
2
 among cases and controls (n=60) 
 
 
 
 
  
Correlation between AMH levels (ng/ml) and E2 (pg/ml) levels 
 
 
Group 
Mean E2 
levels 
(pg/ml) 
Standard 
deviation 
Pearson 
correlation 
p value 
Cases (30) 71.18 10.88 -0.119 0.531 
Controls (30) 73.70 12.50 0.039 0.838 
 
 
In subjects with PCOS, AMH levels had a negative linear relationship 
with E2 levels but this correlation was not statistically significant while AMH 
levels in control subjects had a positive linear relationship with E2 levels but this 
correlation was also not statistically significant. 
 
Table 19: Correlation between AMH levels (ng/ml) and E2 (pg/ml) levels among 
cases and controls (n=60) 
 
 
 
  
 
 
 
 
 
Figure 15: Scatter plot comparison of anti-mullerian hormone levels (ng/ml) 
and E2 levels (pg/ml) among cases and controls (n=60) 
 
 
 
  
 
Figure 16: showing ROC curve of AMH levels (ng/ml) in PCOS (n=60) 
 
Area under the curve (AUC): 0.999 
p value for AUC : <0.001*  (significant at 0.05 level) 
 
 
 
 
 
 
  
ROC data table for cut-off of AMH levels 
 
 
PCOS Positive if 
AMH level ≥ 
(ng/ml) 
Sensitivity 1 - Specificity 
1.52 to 5.545 1.000 0.967 to 0.100 
5.595 1.000 0.033 
5.70 0.967 0.033 
5.90 0.967 0.000 
6.40 0.933 0.000 
7.00 0.833 0.000 
 
Table 20: ROC data table for cut-off of AMH levels (ng/ml) in PCOS (n=60) 
 
 
 
 
  
Logistic regression of various factors with PCOS 
 
 
INDEPENDENT 
VARIABLE (N) 
Odds Ratio (95% CI) for 
PCOS p value 
Age in years (continuous) 
 
0.992 (0.906 – 1.085) 
0.854 
LH (mIU/ml) 
 
1.262 (1.080 – 1.475) 
0.003 
FSH (mIU/ml) 1.010 (0.817 to 1.250) 0.923 
Testosterone levels(ng/ml) 1.102 (1.046 to 1.161) <0.001 
AMH levels( ng/ml) 485.11 (241.32 to 756.40) <0.001 
 
Table 21 Logistic regression of various factors with PCOS (n=60) 
 
Serum AMH cut-off level in diagnosing PCOS 
1. If we fix AMH level of 5.595 (~6) as a cut-off, sensitivity was 100% in 
diagnosing all cases of PCOS but 3.3% cases reported false positivity. 
2. If we fix AMH level of 5.7 as a cut-off, sensitivity was 96.7% in diagnosing 
cases of PCOS but 3.3% cases reported false positivity. 
3. If we fix AMH level of 5.9 as a cut-off, sensitivity was 96.7% in diagnosing 
cases of PCOS with a specificity of 100% (no false positives). 
4. If we fix AMH level of 6.4 as a cut-off, sensitivity was 93.3% in diagnosing 
cases of PCOS with a specificity of 100% (no false positives). 
5. Based on the current study findings and ROC data table, the cut-off for AMH 
level between 5.59 to 5.9 units seems appropriate in delineating PCOS subjects 
and control subjects as it has high level of sensitivity and specificity. 
Logistic regression of various factors with PCOS shows that 
1. From the above table it is clear that the variable which has maximum influence 
on the occurrence of PCOS is the serum anti-mullerian hormone levels. 
2. The odds ratio for age and FSH levels were not significant and hence cannot be 
accounted as an association with the occurrence of PCOS 
3. Elevated serum levels of LH, testosterone and AMH were found statistically 
significant predictors of PCOS, with AMH levels demonstrating high odds for 
developing the diseas 
 
 
  
Data analysis 
Data were computer analyzed using SPSS/ PC (Statistical Package for the 
Social Science Inc. Chicago, Illinois USA, version 13.0) statistical package.Simple 
distribution of the study variables and cross tabulation were applied.The independent-
sample t-test procedure was used to compare means of quantitative variables by 
dividing cases into two qualitative groups such as the relationship between patient and 
controls hormones.  
The results in all the above mentioned procedures were accepted as statistically 
significant when the p-value was less than 5% (p<0.05). 
 
 
 
 
 
 
 
 
 
DISCUSSION 
Our present study shows that serum AMH levels were low and at the mean 
value of 3.65 ±1.46 in Normoovulatory women. This study shows serum AMH was 
higher with a mean value of 11.28±5.29 in Anovulatory PCOS women. Our  study 
shows statistical evidence that the mean AMH levels in controls decrease with 
increasing age. In PCOS Serum AMH levels increased 2- to 3-fold higher than in 
control women. 
Beyond the age of 38 years the control women had  very low serum AMH 
levels than with women with PCOS . AMH levels were not statistically significant 
with age and showed a negative relationship. As age increases in control subjects, 
AMH level tend to decrease 
The above inference is supported by studies of Terhi Piltonen.et.al68. 
In the present study the statistical evidence shows that the mean AMH value is 
not having any significant correlation with LH in control subjects .In subjects with 
PCOS, AMH levels had a negative relationship and was not statistically significant 
with LH levels. This is due to the small sample size taken up in the study. 
 This evidence is supported by the study Artemis Karkanaki.et.al69.The 
Control subjects also had a negative linear relationship with FSH levels and this 
correlation was not statistically significant .In subjects with PCOS, AMH levels had a 
negative linear relationship with FSH levels and this correlation was found to be 
statistically significant with AMH levels. 
The above correlation is supported by the study A.La.Marca .et.al70. 
AMH levels in control subjects also had a positive linear relationship with 
combined antral follicular count but this correlation was not statistically significant. In 
subjects with PCOS, AMH levels had a positive linear relationship with combined 
antral follicular count and this correlation was statistically significant. 
      This is supported by the study.D.Dewailly .et.al71.        
AMH levels in control subjects also had a positive linear relationship with 
combined ovarian volume but this correlation was not statistically significant. In 
subjects with PCOS, AMH levels had a positive linear relationship with combined 
ovarian volume and this correlation was statistically significant .While  AMH levels in 
control subjects had a positive and a linear relationship with E2 levels but this was also 
not statistically significant In subjects with PCOS, AMH levels had a negative linear 
relationship with E2 levels but this was also not statistically significant  
This is supported by the study Maxwell Omabe .et.al72.       
 In both subjects with PCOS and control subjects, AMH levels had a negative 
linear relationship with testosterone levels but this correlation was not statistically 
significant. AMH levels in control subjects had a negative linear relationship with 
BMI but this correlation was also not statistically significant .In subjects with PCOS, 
AMH levels had a positive linear relationship with BMI but this correlation was not 
statistically significant.  
The AMH ROC shows that the area under the curve represents the probability 
that the AMH level for a randomly chosen positive (PCOS) case will exceed the result 
for a randomly chosen negative (control) case. Hence the AMH levels of a PCOS 
subject have a probability of >99% to be higher than AMH levels of a control subject. 
Therefore it can be said that AMH assay has a very high validity in PCOS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                                                CONCLUSION 
AMH IN NORMOOVULATORY AND PCOS WOMEN 
In PCOS there was a marked increase in the serum AMH levels which is of 
great diagnostic value.Anovulation in PCOS is where the AMH appears to have a 
major inhibitory role by interfering with during folliculogenesis AMH may be of 
value in differential diagnosis of oligomenorrhea and it reflects the future of revision 
of the criteria for the diagnosis of PCOS. 
Measurement of AMH can provide a high specificity and sensitivity (92% and 
67% respectively) by which it can act as a marker for PCOS. In situations where 
accurate ultrasonography data are not available this based on the above findings it can 
be proposed that, in the  diagnostic criterion for PCOS than the follicular count. 
This can aid in the recoiling the Rotterdam consensus and other definitions for 
PCOS, especially in women having the Rotterdam PCOS phenotype without HA. We 
thus propose a simple strategy for the diagnosis of PCOS in clinical practice. 
 
 
 
 
 
  
 
           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                              ANNEXURE 
 
 
 
 
 
 
 
 
  
 
MASTER SHEET 
STUDY CASES 
S:NO Age LH 
mIU/ml 
FSH T3 T4 TSH 
µIU/ml 
TESTO 
ng/ml 
AMH 
ng/ml mIU/m pg/ml ng/ml 
1 28 8.88 4.02 1.9 1.2 1.8 75.98 11.6 
2 22 14.51 7.31 2.7 1.2 2.4 53.22 15.9 
3 20 7.5 5.72 2.76 1.06 3.84 47.15 29.4 
4 29 14.95 7.6 2.51 1.2 2.97 102.3 15.2 
5 31 7.59 3.2 3.6 1.3 2.9 112.42 19.4 
6 20 7.09 5.5. 3.33 0.6 2.9 62.14 18.5 
7 21 13.67 4.89 3.45 0.9 4.6 55.11 15.7 
8 24 8.76 4.36 3.15 1. 36 1.77 83.04 16.2 
9 35 3.31 7.97 3.15 1.2 1.4 66.02 12.5 
10 25 3.9 6.32 1.6 0.9 1.5 95.32 12.3 
11 24 7.07 2.68 2.98 1. 13 4.5 33.73 17.7 
12 26 12.07 4.08 3.15 1.03 4 60.11 8.7 
13 25 12.36 7.2 1.38 2.2 4.7 79.25 8.5 
14 34 8.88 4.02 2.4 1.5 1.9 75.98 11.5 
15 35 11.59 3.56 2.21 2.3 1.4 81.65 12.6 
16 23 7.2 3.2 1.24 0.9 4.1 70.07 6.8 
17 24 9.7 5.9 1.54 1.6 4.1 80.02 8.7 
18 21 10.34 6.87 1.2 1.2 3.6 40.12 5.6 
19 18 15 7 1.08 1.2 3 72.46 8.7 
20 24 12.2 6.9 1.14 1.5 3.7 46.86 6.8 
21 26 11.8 7.4 1.12 1.1 3.7 70.46 7.8 
22 23 11.5 4.47 1.24 1.5 2.2 86.12 9 
23 25 11.2 8.2 1.14 0.9 1.4 99.51 6 
24 29 14 4.6 1.24 1 0.8 94.58 7.6 
25 24 16.13 6.9 1.8 1.2 2.3 74.45 7.2 
26 22 9.05 7.8 1.42 1.3 3.5 82.67 7.8 
27 30 15 8 1.75 1.4 4.1 70.95 8.7 
28 23 9.7 5.9 1.66 1.1 3.1 58.41 6.8 
29 14 11.8 7.4 1.5 1.5 3.5 58.29 7.4 
30 30 11.5 4.57 2.7 1.6 3.6 102.36 7.8 
 
 
  
STUDY CASE 
PROLACTIN 
ng/ml 
AFC AFC Rt   Ovary Lt  Ovary BMI E2 
Rt ovary Lf ovary 
volume 
cm3 
volume 
cm3 Kg/m2  pg/ml 
6.47 13 12 16 20 28.62 45 
10.46 12 15 17 16 32.03 62 
12.54 18 19 20 22 30.78 64 
7.68 17 16 18 17 28.93 90 
6.34 20 18 22 19 36.98 66.5 
8.97 17 16 17.6 10 26.5 76 
11.28 12 16 11 17 29.15 88 
23.57 14 18 7.2 15.93 27.89 77 
8.88 12 17 13 19 23.31 68 
9.99 12 16 12 16 29.49 77 
11.11 17 18 16 19 24.62 62 
3.09 17 18 17 17.4 32.73 70 
8.36 12 17 13 12 26.69 71 
6.47 17 17 17 19 28.69 66 
 13.52 16 18 18 19 21.45 48 
6.04 14 12 10 12 16.82 62 
08-Jan 13 12 13 10 28.23 88 
6.84 15 12 17 14 39.48 77 
6.04 14 12 15 12 30.36 80 
10.1 16 14 11 15 27.48 68 
11.1 12 14 13 16 27.85 62 
12.8 12 18 13 19 32.33 60 
12.3 17 12 13 10 30.5 62 
6.8 15 18 12 19 32.89 76 
10.16 12 18 11 21 24.86 70 
7.64 18 15 11 20 26.84 80 
10.75 13 16 13 14 18.83 80 
11.4 17 8 13 10 24.97 78 
6.04 13 18 15 11 30.96 80 
8.9 14 15 15 17 33.78 82 
 
  
STUDY CONTROL 
S:NO Age LH 
mIU/ml 
FSH 
mIU/m 
T3 
pg/ml 
T4   
ng/ml 
TSH 
µIU/ml 
F.TESTO 
ng/ml 
AMH 
ng/ml 
1 27 9.9 2.11 1.63 1.7 5.4 30.23 5.5 
2 21 10.34 6.87 1.52 8 3.6 40.12 5.59 
3 26 11.2 8.2 3.1 1.7 0.19 30.07 5 
4 29 14 7.04 1.96 1.8 2.04 50.87 5.04 
5 18 15 3.06 1.74 1.2 4.05 50.08 5.3 
6 23 6.2 4.1 1.98 1.4 4 40.05 5.8 
7 27 10.65 7.87 3.21 1.15 5.12 52.36 0.9 
8 28 14.15 6.21 3.1 1.05 5.21 67.35 4.73 
9 21 7.21 7.33 3.46 1.16 2.27 70.18 5.4 
10 35 8.27 4.55 2.34 1.11 1.32 60.42 4.39 
11 35 3.31 7.79 3.15 1.21 1.39 66.02 2.5 
12 36 6.09 9.6 3.67 1.55 3.91 50.77 3.74 
13 25 6.64 4.67 3.41 1.03 2.13 51.91 5.4 
14 26 12.7 2.11 2.4 1.4 2 50.17 5.5 
15 32 10.96 8.54 1.7 1.08 2.9 60.13 2.14 
16 22 1.53 4.58 2.7 1.3 2.9 62.5 4.11 
17 25 6.2 13.65 2.7 1.3 2.9 62.5 2.2 
18 40 3.95 4.12 1.7 1.5 1.4 44.51 2.26 
19 30 5.4 7.71 1.9 1.2 2.2 62.51 2.62 
20 25 9.7 5.93 2.1 1.1 0.9 56.19 2.42 
21 38 1.85 6.72 2.6 1.3 2.4 57.18 2.29 
22 30 3.12 4.02 1.8 1.2 2.1 52.18 2.4 
23 30 9.05 1.66 2.1 1.4 1.5 51.35 2.28 
24 25 10.34 6.87 2.6 1.4 1.2 4.04 5.59 
25 34 10 6.06 1.8 1.2 1.3 48.58 2.52 
26 39 3.17 4.43 2.2 1.1 1.7 46.4 2.85 
27 26 0.79 1.92 2.3 1.5 1.7 41.45 2.15 
28 29 4.95 1.95 2 1.7 2.1 50.5 2.93 
29 35 1.67 1.2 2.2 1.2 1.4 47.41 2.93 
30 28 3.6 5.4 2.1 1.4 1.8 40.42 3.25 
 
 
 STUDY CONTROL 
PROLACTIN 
ng/ml AFC 
Rt ovary 
AFC 
Lf ovary 
Rt 
volume 
cm3 
Lf 
volume 
cm3 
BMI  
Kg/m2 
E2 
pg/ml 
20.17 5 5 5 6 34.72 76 
3.1 5 4 5 4 39.48 74 
21 4 6 5 7 19.71 80 
24 6 4 7 5 24 62 
 9.12 4 5 6 7 25.76 64 
10.31 3 5 5 7 23.35 80 
15.2 4 3 5 4 28.57 90 
14.74 6 4 7 6 23.79 92 
12.31 4 5 6 5 19.69 66 
8.01 5 6 6 7 24.76 77 
8.88 4 5 5 6 21.69 84 
9.84 3 5 4 5 29.43 62 
10.26 3 2 3 2.5 28.44 76 
20.14 4 4 3.9 4 23.75 90 
8.02 6 5 7 4 25.62 86 
8.02 4 3 5 6 23.67 90 
8.02 5 4 6 5 32.46 82 
10.24 3 5 5 5 19.74 76 
20.01 4 5 4 5 20.85 62 
8.48 3 5 4 6 36.31 90 
9.02 2 3 3 5 32.64 66 
10.74 3 4 4 5 26.86 45 
12.12 2 4 5 5 29.52 77 
15.26 4 5 5 6 18.95 62 
14.01 3 5 3 6 20.46 70 
15.12 4 4 5 6 21.67 62 
8.24 3 2 4 4 18.59 48 
8.17 4 5 5 7 21.59 66 
23.52 3 4 4 5 28.96 68 
11.31 3 4 5 6 20.76 88 
 
 
 CASE PROFOMA 
 
“A STUDY OF RELATIONSHIP OF ANTIMULLERIAN HORMONE 
IN WOMEN WITH NORMOOVULATORY AND POLY CYSTIC 
OVARIAN SYNDROME” 
 
Name:                                                                                                                 IP/OP.NO:                   
Age/Sex: 
Place: 
 
Socioeconomic status: Low/Middle/High 
 
Chief C/O: 
Ovulatory /Anovulatory- 
 
Infertility- 
 
Menstural H/O: 
Duration-                                                                        
Last Menstural Periods- 
 
Marital H/O: 
Duration- 
Consagunity- 
 
 
 Obstertrics H/O:   
Gravida-         Para-       Living-     Abortion- 
Last Child Birth- 
Past H/O: 
DM/HT/Allergy/Asthma/Treatment/Surgery 
 
Family H/O: 
 
Personal H/O: 
 
General examination: 
Ht:                                                          Wt:                                     BMI: 
RR:                                                           PR:                                      B.P: 
Thyroid: 
Hirsutism: 
Pattern of hair distribution score 
 Upper lip  
 Chin  
 Chest  
 Upper back  
 Lower back  
 Upper abdomen  
 Lower abdomen  
 Upper arms  
 Forearms   
 Thighs  
 Legs   
 
 
  
Systemic examination: 
CVS: 
 
RS: 
 
Abdomen: 
 
CNS: 
 
Investigations: 
CBC: 
FBG: 
LH  
 
FSH  
 
 fT3  
 
fT4  
 
TSH  
 
PRL  
 
T Testosterone  
 
E2  
 
AMH  
 
 
 
 
Ultrasonography: 
Uterus  
 
Ovarian volume 
(OV) 
Rt. Ovary  
(cm3) 
Lf. Ovary 
(Cm3) 
  
 
 
 
Antral follicular 
count (AFC) 
 
         Rt. Ovary 
 
        Lf. Ovary 
 
  
 
 
 
 
 
Semen analysis: 
 
Diagnosis: 
 
Signature of the principle investigator: 
 
 
 
 
 
 
 
 
 
 
 
 
Chennai Medical College Hospital & Research Centre 
Irungalur, Trichy – 621 105.  
Consent Form 
You are requested to participate in a study conducted in the 
Department of Biochemistry, Chennai Medical College Hospital & Research 
Centre, Irungalur, Trichy, Tamilnadu titled “A study of Relationship of 
Antimullerian Hormone in women with Normoovulatory and Poly Cystic 
Ovarian Syndrome”. Your participation in the study is voluntary 
 There will be no cost for  participating in the study 
 Your participation is not a compulsion 
 You have the right to withdraw from the study at any time. 
Nature of Study: 
 If any abnormalities are identified, you will be informed for 
further consultation. 
 The results of this study will be kept confidential 
We believe that the results of this study will be beneficial for advancements 
in medicine & Science.  We assure you that we will not use these result for 
any other purpose. 
Consent 
I Mr /Mrs / Ms______________________________________________________________ 
residing at _____________________________________________________________________ 
____________________________________________________________on this day 
___________________  after having read the consent form carrying information 
for the above mentioned study and I hereby give my consent to take 5ml of 
my blood sample for the purpose of doing diagnostic tests including 
hematological , biochemical investigations. I was explained about the 
procedure in detail and give my consent for participating in the study and 
for using the results for Medical & Scientific purposes. 
 
Signature of the participant    
                                                                                    Signature of the Investigator 
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